Liu Q, Yang J, Lv L, Zhang X, Li M, Xu L
Front Immunol. 2025; 16:1525110.
PMID: 40079007
PMC: 11897025.
DOI: 10.3389/fimmu.2025.1525110.
DiNardo C, Jen W, Takahashi K, Kadia T, Loghavi S, Daver N
Leukemia. 2025; .
PMID: 40000842
DOI: 10.1038/s41375-025-02531-8.
Abedin S, Guru Murthy G, Hamadani M, Michaelis L, Carlson K, Runaas L
Leukemia. 2025; .
PMID: 39955432
DOI: 10.1038/s41375-025-02528-3.
Gyan E, Minden M, Kubo K, Rambaldi A, Juliusson G, Jadersten M
Cancer. 2025; 131(4):e35746.
PMID: 39945223
PMC: 11822735.
DOI: 10.1002/cncr.35746.
Rodriguez-Goncer I, Boan J, Carrero-Arribas R, Sanchez-Pina J, Lizasoain M, Fernandez-Ruiz M
Open Forum Infect Dis. 2025; 12(2):ofaf025.
PMID: 39917333
PMC: 11800478.
DOI: 10.1093/ofid/ofaf025.
Identification of hub genes and immune-related pathways in acute myeloid leukemia: insights from bioinformatics and experimental validation.
Shan M, Xu L, Yang W, Liu S, Cui Z
Front Immunol. 2025; 15:1511824.
PMID: 39867885
PMC: 11757261.
DOI: 10.3389/fimmu.2024.1511824.
A Nomogram Built on Clinical Factors and CT Attenuation Scores for Predicting Treatment Response of Acute Myeloid Leukemia Patients.
Liu L, Lu W, Xiong L, Qi H, Gale R, Yin B
Biomedicines. 2025; 13(1).
PMID: 39857781
PMC: 11763309.
DOI: 10.3390/biomedicines13010198.
Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.
Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N
Bone Marrow Transplant. 2025; .
PMID: 39838078
DOI: 10.1038/s41409-025-02508-2.
The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.
Xu J, Song C, He Y, Huang R, Tu S
BMC Pharmacol Toxicol. 2025; 26(1):10.
PMID: 39833882
PMC: 11744839.
DOI: 10.1186/s40360-025-00839-w.
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Cortes J, Roboz G, Baer M, Jonas B, Schiller G, Yee K
J Hematol Oncol. 2025; 18(1):7.
PMID: 39819505
PMC: 11736922.
DOI: 10.1186/s13045-024-01657-z.
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies.
Puzo C, Seropian S, Rinder H, Tormey C, Siddon A
Bone Marrow Transplant. 2025; .
PMID: 39806028
DOI: 10.1038/s41409-025-02510-8.
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Onate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M
Blood Cancer J. 2025; 15(1):4.
PMID: 39799145
PMC: 11724937.
DOI: 10.1038/s41408-024-01205-5.
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience.
McCall D, Alqahtani S, Budak M, Sheikh I, Fan A, Ramakrishnan R
Cancers (Basel). 2024; 16(22).
PMID: 39594839
PMC: 11592422.
DOI: 10.3390/cancers16223886.
Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia.
Wu Y, Liang J, Mi R, Wang L, Chen L, Wei X
Sci Rep. 2024; 14(1):29161.
PMID: 39587191
PMC: 11589753.
DOI: 10.1038/s41598-024-80496-x.
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell N, Thomas A, Hills R, Thomas I, Gilkes A, Almuina N
J Clin Oncol. 2024; 43(6):694-704.
PMID: 39556780
PMC: 11825491.
DOI: 10.1200/JCO.24.00259.
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodriguez-Arboli E, Rodriguez-Veiga R, Soria-Saldise E, Bergua J, Caballero-Velazquez T, Arnan M
Cancer. 2024; 131(1):e35618.
PMID: 39476204
PMC: 11694237.
DOI: 10.1002/cncr.35618.
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S
Blood Adv. 2024; 9(4):752-758.
PMID: 39454204
PMC: 11869862.
DOI: 10.1182/bloodadvances.2024014279.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.
Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J
EJHaem. 2024; 5(5):951-956.
PMID: 39415930
PMC: 11474352.
DOI: 10.1002/jha2.991.
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.
Kayser S, Sanber K, Marconi G, Mattei A, Luskin M, Kelkar A
Haematologica. 2024; 110(2):378-384.
PMID: 39363862
PMC: 11788626.
DOI: 10.3324/haematol.2024.285985.
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.
Costa A, Gurnari C, Scalzulli E, Cicconi L, Guarnera L, Carmosino I
Cancers (Basel). 2024; 16(18).
PMID: 39335185
PMC: 11429657.
DOI: 10.3390/cancers16183214.